MedTrace Logo

Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

NCT00395291 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2017-02-20

Study results available
· View outcomes & findings →

Summary

The objective of this study is to determine MK-0677 increases IGF-1 in patients with end stage renal disease (ESRD) on hemodialysis.

Conditions

Interventions

DRUG

MK-0677

The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.

DRUG

Placebo

Placebo

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • University of Virginia

    lead OTHER

Principal Investigators

  • Warren K Bolton, MD · University of Virginia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-08-31
Primary Completion
2009-01-31
Completion
2010-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00395291 on ClinicalTrials.gov